PharmaDeals® Deal Making Spotlight Reports - 5 companies

During 2005, seven of the top ten licensing or co-development deals (in terms of total potential value) involved one of the five companies featured in the Spotlight Reports big pharma series. These reports will be invaluable to companies that are looking to collaborate with one of these five companies. By examining equivalent deals in these reports, you will also be able to benchmark your deal with any potential big pharma partner.

A full description of the deal terms between the two companies gives you all the information required to understand a deal at a glance. Where possible, full financial details of the deal are described, including information such as upfront payments, potential milestone payments and the royalties agreed between the parties.

Analysis of the information within the Spotlight Reports has been performed by PharmaVentures Business Analysts, providing you with a concise breakdown of each company's deal making trends. All significant updates are included for each deal and, with online access to PharmaDeals Agreements included, you can track the progress of individual deals and take advantage of the fully searchable features of this essential management tool.

> Deal Making Spotlight on Pfizer

> Deal Making Spotlight on sanofi-aventis

> Deal Making Spotlight on GlaxoSmithKline

> Deal Making Spotlight on Johnson & Johnson

> Deal Making Spotlight on Novartis

Detailing the deal making activities of the top 5 pharmaceutical companies, from 2000 up to and including the whole of 2005, if you are looking to partner with big pharma, these reports are crucial to your deal making strategy.

Each report is:

> Insightful - Presents and discusses the deal making activities of the company and its subsidiaries over a 5-year period. Key trends are identified, providing you with full information about your potential partner.

> Analytical - Comparative analysis is made between the deal making activities of the top 5 pharmaceutical companies, and within the industry as a whole. Analysis of deal making trends identifies: which phase each company deals at; how much each company pays for deals; what type of deals are made; what therapy areas are represented. This ensures you have the full information you need to plan the next step towards your deal.

> Comprehensive - The deal making profile covers all deals made by the company and its subsidiaries between 2000 and 2005. Commentary is supported by full lists of deals made as well as articles that provide in-depth analysis of key deals made by the company in question.

See individual reports below.
Price: $2,970.00 / GBP1,633.50

Deal Making Spotlight on Novartis
During 2005, seven of the top ten licensing or co-development deals (in terms of total potential value) involved one of the five companies featured in the Spotlight Reports big pharma series. These reports will be invaluable to companies that are looking to collaborate with one of these five companies. By examining equivalent deals in these reports, you will also be able to benchmark your deal with any potential big pharma partner.

Deal Making Spotlight on Johnson and Johnson
During 2005, seven of the top ten licensing or co-development deals (in terms of total potential value) involved one of the five companies featured in the Spotlight Reports big pharma series. These reports will be invaluable to companies that are looking to collaborate with one of these five companies. By examining equivalent deals in these reports, you will also be able to benchmark your deal with any potential big pharma partner.

Deal Making Spotlight on GlaxoSmithKline
During 2005, seven of the top ten licensing or co-development deals (in terms of total potential value) involved one of the five companies featured in the Spotlight Reports big pharma series. These reports will be invaluable to companies that are looking to collaborate with one of these five companies. By examining equivalent deals in these reports, you will also be able to benchmark your deal with any potential big pharma partner.

Deal Making Spotlight on sanofi-aventis
During 2005, seven of the top ten licensing or co-development deals (in terms of total potential value) involved one of the five companies featured in the Spotlight Reports big pharma series. These reports will be invaluable to companies that are looking to collaborate with one of these five companies. By examining equivalent deals in these reports, you will also be able to benchmark your deal with any potential big pharma partner.

Deal Making Spotlight on Pfizer
During 2005, seven of the top ten licensing or co-development deals (in terms of total potential value) involved one of the five companies featured in the Spotlight Reports big pharma series. These reports will be invaluable to companies that are looking to collaborate with one of these five companies. By examining equivalent deals in these reports, you will also be able to benchmark your deal with any potential big pharma partner.

Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.